Project Grant HT94252410912
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The University of British Columbia (UBC) received a $1,731,421.95 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) to provide advanced physiologic monitoring at the site of spinal cord injury. The 3-year project, with a start date of September 30, 2023, will focus on transforming healthcare for Service Members and the public through innovative and impactful research into medical solutions for the battlefield. As the...
The University of British Columbia (UBC), through its Research Services division, has been awarded a $407,599 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 2-year research project titled "Epigenetic and Metabolomics Vulnerabilities in ASCL1-Driven NEPC Subtype" starting on September 1, 2024. This grant allows UBC researchers to leverage their expertise in biomedical research to...
The University of British Columbia was awarded a $2,498,328 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on using blood biomarkers to improve diagnosis of brain injury and assess dementia risk in survivors of intimate partner violence. The 4-year grant, awarded on June 1, 2024, will enable UBC researchers to leverage their expertise in biomedical research, clinical trials, and data analysis to...
The University of British Columbia (UBC) was awarded a $561,584 project grant by the Defense Health Agency to conduct research on the measurement and impact of body composition using CT imaging in patients with germ cell tumors undergoing chemotherapy. This grant is funded under the Military Medical Research and Development Program (CFDA 12.420), which supports biomedical research to transform healthcare for service members and the public through innovative and impactful research, including...
The federal Project Grant award of $1,868,800.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports a research project titled "The Effect of Cardiocentric Hemodynamic Management of Acutely Injured Individuals with Cervical Spinal Cord Injury on Cardiovascular Outcomes", to be conducted by the University of British Columbia over the period of September 1, 2025 to August 31, 2028. The University of...
The University of British Columbia received a $1.7 million project grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The three-year award will support research into noninvasive spinal cord stimulation for recovery of autonomic function after spinal cord injury. Specifically, the university researchers will work to move promising mechanistic findings into clinical practice by investigating medical...
The University of British Columbia (UBC) received a $507,035 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420). The grant, awarded on September 1, 2023, will fund research for "The Ovarian Cancer Observatory: Prevention, Impact, and Learning from Opportunistic Salpingectomy" over a 4-year period through August 31, 2027. As the prime grantee, UBC will leverage its expertise in medical research and data analysis...
The University of British Columbia (UBC) was awarded a $525,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) to engineer an effective combination therapy involving car T cells and regulatory T cells to control vascular composite allograft (VCA) rejection. The 3-year project, running from August 1, 2023 to July 31, 2026, will focus on developing innovative medical solutions to address transplant rejection issues for service...
This federal Project Grant award of $426,154 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of British Columbia (UBC) to investigate immunological landscapes in neuroendocrine prostate cancer. The goal is to develop strategies for enhancing the efficacy of immunotherapy. UBC, a prominent public research university in Canada, will leverage its advanced research capabilities and expertise in...
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...